JOP20220105A1 - مجموعات سلفون أميد أمينو أريل غير متجانس بها 5 ذرات لعلاج حالات يتوسط في حدوثها نشاط cftr - Google Patents
مجموعات سلفون أميد أمينو أريل غير متجانس بها 5 ذرات لعلاج حالات يتوسط في حدوثها نشاط cftrInfo
- Publication number
- JOP20220105A1 JOP20220105A1 JOP/2022/0105A JOP20220105A JOP20220105A1 JO P20220105 A1 JOP20220105 A1 JO P20220105A1 JO P20220105 A JOP20220105 A JO P20220105A JO P20220105 A1 JOP20220105 A1 JO P20220105A1
- Authority
- JO
- Jordan
- Prior art keywords
- conditions mediated
- cftr activity
- treating conditions
- sulfonamide groups
- heterocyclic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/222—Amides of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962934293P | 2019-11-12 | 2019-11-12 | |
| PCT/US2020/060180 WO2021097057A1 (en) | 2019-11-12 | 2020-11-12 | 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient cftr activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20220105A1 true JOP20220105A1 (ar) | 2023-01-30 |
Family
ID=73740547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2022/0105A JOP20220105A1 (ar) | 2019-11-12 | 2022-05-10 | مجموعات سلفون أميد أمينو أريل غير متجانس بها 5 ذرات لعلاج حالات يتوسط في حدوثها نشاط cftr |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20240002374A1 (https=) |
| EP (1) | EP4058439A1 (https=) |
| JP (2) | JP7721517B2 (https=) |
| KR (1) | KR20220115829A (https=) |
| CN (1) | CN115003659B (https=) |
| AU (1) | AU2020384279A1 (https=) |
| BR (1) | BR112022009185A2 (https=) |
| CA (1) | CA3158057A1 (https=) |
| CL (1) | CL2022001245A1 (https=) |
| CO (1) | CO2022007953A2 (https=) |
| EC (1) | ECSP22046050A (https=) |
| IL (1) | IL292966A (https=) |
| JO (1) | JOP20220105A1 (https=) |
| MX (1) | MX2022005809A (https=) |
| PE (1) | PE20221461A1 (https=) |
| PH (1) | PH12022551139A1 (https=) |
| WO (1) | WO2021097057A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7214743B2 (ja) | 2018-02-15 | 2023-01-30 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターとしての大環状分子、それらの医薬組成物、嚢胞性線維症の治療におけるそれらの使用、及びそれらの製造方法 |
| UY38630A (es) | 2019-04-03 | 2020-10-30 | Vertex Pharma | Agentes moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| TWI899097B (zh) | 2019-08-14 | 2025-10-01 | 美商維泰克斯製藥公司 | 製備cftr調節劑之方法 |
| WO2021030552A1 (en) | 2019-08-14 | 2021-02-18 | Vertex Pharmaceuticals Incorporated | Crystalline forms of cftr modulators |
| EP4058434A1 (en) | 2019-11-12 | 2022-09-21 | Genzyme Corporation | 6-membered heteroarylaminosulfonamides for treating diseases and conditions mediated by deficient cftr activity |
| EP4225737A1 (en) * | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| KR20230118123A (ko) | 2020-12-10 | 2023-08-10 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 치료 방법 |
| CN113480416B (zh) * | 2021-07-12 | 2023-03-21 | 重庆大学 | 一种芳基酮的制备方法 |
| KR20240168370A (ko) | 2022-03-30 | 2024-11-29 | 이시하라 산교 가부시끼가이샤 | 피리다지논계 화합물 또는 그의 염 및 그들을 함유하는 유해 생물 방제제 |
| CN114835655A (zh) * | 2022-04-14 | 2022-08-02 | 河南师范大学 | 一种合成光学活性三氟甲基丙烯酸酯类化合物的方法 |
| EP4611742A1 (en) | 2022-10-31 | 2025-09-10 | Sionna Therapeutics Inc. | Methods of treating cftr-mediated diseases or disorders |
| WO2025017207A1 (en) * | 2023-07-20 | 2025-01-23 | Cemm - Forschungszentrum Für Molekulare Medizin Gmbh | Inhibitors of smndc1 and their therapeutic use |
| WO2025076235A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU654125B2 (en) * | 1991-03-07 | 1994-10-27 | Hisamitsu Pharmaceutical Co., Inc. | Novel diphenylthyazole derivative |
| AU689972B2 (en) * | 1994-11-29 | 1998-04-09 | Hisamitsu Pharmaceutical Co., Inc. | Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof |
| US20050004134A1 (en) * | 2001-11-08 | 2005-01-06 | Hideo Tsutsumi | Thiazole derivative and pharmaceutical use thereof |
| RU2006111093A (ru) * | 2003-09-06 | 2007-10-27 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Модуляторы атр-связывающих кассетных транспортеров |
| BR112013031485B1 (pt) * | 2011-06-10 | 2022-06-14 | Medimmune, Llc | Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais |
| WO2016183173A1 (en) * | 2015-05-12 | 2016-11-17 | Avista Pharma Solutions | Antiparasitic compounds |
| US10138227B2 (en) * | 2016-06-03 | 2018-11-27 | Abbvie S.Á.R.L. | Heteroaryl substituted pyridines and methods of use |
| TW201811766A (zh) * | 2016-08-29 | 2018-04-01 | 瑞士商諾華公司 | N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途 |
| EP4611742A1 (en) * | 2022-10-31 | 2025-09-10 | Sionna Therapeutics Inc. | Methods of treating cftr-mediated diseases or disorders |
-
2020
- 2020-11-12 MX MX2022005809A patent/MX2022005809A/es unknown
- 2020-11-12 IL IL292966A patent/IL292966A/en unknown
- 2020-11-12 EP EP20820656.5A patent/EP4058439A1/en active Pending
- 2020-11-12 CN CN202080092755.2A patent/CN115003659B/zh active Active
- 2020-11-12 PH PH1/2022/551139A patent/PH12022551139A1/en unknown
- 2020-11-12 PE PE2022000772A patent/PE20221461A1/es unknown
- 2020-11-12 AU AU2020384279A patent/AU2020384279A1/en active Pending
- 2020-11-12 BR BR112022009185A patent/BR112022009185A2/pt unknown
- 2020-11-12 KR KR1020227019502A patent/KR20220115829A/ko active Pending
- 2020-11-12 WO PCT/US2020/060180 patent/WO2021097057A1/en not_active Ceased
- 2020-11-12 JP JP2022527081A patent/JP7721517B2/ja active Active
- 2020-11-12 CA CA3158057A patent/CA3158057A1/en active Pending
-
2022
- 2022-05-10 JO JOP/2022/0105A patent/JOP20220105A1/ar unknown
- 2022-05-11 US US17/742,169 patent/US20240002374A1/en active Pending
- 2022-05-12 CL CL2022001245A patent/CL2022001245A1/es unknown
- 2022-06-03 CO CONC2022/0007953A patent/CO2022007953A2/es unknown
- 2022-06-09 EC ECSENADI202246050A patent/ECSP22046050A/es unknown
-
2025
- 2025-07-30 JP JP2025126773A patent/JP2025160375A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112022009185A2 (pt) | 2022-07-26 |
| US20240002374A1 (en) | 2024-01-04 |
| PH12022551139A1 (en) | 2023-07-17 |
| AU2020384279A1 (en) | 2022-05-26 |
| MX2022005809A (es) | 2022-06-08 |
| CN115003659A (zh) | 2022-09-02 |
| WO2021097057A1 (en) | 2021-05-20 |
| CN115003659B (zh) | 2026-04-21 |
| IL292966A (en) | 2022-07-01 |
| ECSP22046050A (es) | 2022-08-31 |
| JP2023500408A (ja) | 2023-01-05 |
| PE20221461A1 (es) | 2022-09-21 |
| JP2025160375A (ja) | 2025-10-22 |
| CL2022001245A1 (es) | 2023-03-10 |
| EP4058439A1 (en) | 2022-09-21 |
| JP7721517B2 (ja) | 2025-08-12 |
| CO2022007953A2 (es) | 2022-09-09 |
| CA3158057A1 (en) | 2021-05-20 |
| KR20220115829A (ko) | 2022-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220105A1 (ar) | مجموعات سلفون أميد أمينو أريل غير متجانس بها 5 ذرات لعلاج حالات يتوسط في حدوثها نشاط cftr | |
| JOP20220106A1 (ar) | مجموعات سلفون أميد أمينو أريل غير متجانس بها 6 ذرات لعلاج أمراض وحالات يتوسط في حدوثها نشاط cftr | |
| EP4506001A3 (en) | SUBSTITUTED TETRAHYDROFURANS AS SODIUM CHANNEL MODULATORS | |
| JOP20230318A1 (ar) | مشتقات تترا هيدرو – إيميدازوبيريدين كمعدِّلات مناعية pd-l1 | |
| MX2019013954A (es) | Inhibidores covalentes de kras. | |
| MX2024002519A (es) | Compuestos de indol y metodos de uso. | |
| MX2023004923A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| MX385054B (es) | Piridinas sustituidas con heteroarilo y metodos de uso. | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| WO2017132432A8 (en) | Benzimidazole derivatives as modulators of ror-gamma | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| CY1125488T1 (el) | Παραγωγα πυριδινης και θεραπευτικες χρησεις αυτων ως αναστολεις trpc6 | |
| JOP20190125A1 (ar) | مُعدِّل لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل | |
| PH12018500088A1 (en) | Substituted tricyclics and method of use | |
| WO2016164675A8 (en) | Substituted quinazoline compounds and methods of use thereof | |
| MX380928B (es) | Inhibidores de kras g12c. | |
| WO2017087608A8 (en) | Modulators of ror-gamma | |
| CR20210480A (es) | Formulaciones farmacéuticas | |
| PH12018501285A1 (en) | Alkyl dihydroquinoline sulfonamide compounds | |
| MX2023005913A (es) | Derivados de bencenosulfonamida y usos de los mismos. | |
| PH12021551396A1 (en) | Active ester derivatives of testosterone, compositions and uses thereof | |
| MX2017012188A (es) | Inhibidores de beta-secretasa 1 (bace1). | |
| JOP20240265A1 (ar) | مركبات وتراكيب وطرق استخدامها | |
| EA202092013A1 (ru) | Пиридинкарбонильные производные и их терапевтические применения в качестве ингибиторов trpc6 | |
| EA201992005A1 (ru) | Арильные, гетероарильные и гетероциклические фармацевтические соединения для лечения медицинских нарушений |